Herpes Simplex 2 IgM (HSV-2 IgM) ELISA kit
|Category Name||TORCH Panel|
|Method||ELISA method: Enzyme Linked Immunosorbent Assay|
|Principle||ELISA principle- Indirect; Antigen Coated Plate|
|Detection Range||Qualitative elisa assay- Positive, Negative and Cut-off|
The DIAGNOSTIC AUTOMATION ELISA, HSV 2 IgM is intended for the detection of IgM antibodies to herpes simplex virus 2.
Purified HSV antigen is coated on the surface of microwells. Diluted patient serum is added to wells, and the HSV 2 IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away. After adding enzyme conjugate, it binds to the antibody-antigen complex. Excess enzyme conjugate is washed off and TMB Chromogenic substrate is added. The enzyme conjugate catalytic reaction is stopped at a specific time. The intensity of the color generated is proportional to the amount of IgM 2 specific antibody in the sample. The results are read by a microwell reader compared in a parallel manner with calibrator and controls.
The precision of the assay was evaluated by testing three different sera of eight replicates over a period of one week. The intra-assay and inter-assay C.V. are summarized below:
To prevent false negative and false positive IgM test results caused by the presence of specific IgG and rheumatoid factor (RF) in some specimens, reagents provided in this kit has been formulated to resolve these interferences. However, specimens with extremely high RF and high autoimmune antibodies, the possibility of these interferences cannot be ruled out entirely. As with other serological assays, the results of these assays should be used in conjunction with information available from clinical evaluation and other diagnostic procedures.
A negative serological test does not exclude the possibility of past infection. Following primary HSV infection, antibody may fall to undetectable levels and then be boosted by later clinical infection with the same or heterologous type. Such a phenomenon may lead to incorrect interpretations of seroconversion and primary infection, or negative antibody status. In addition, samples obtained too early during primary infection may not contain detectable antibody. Some persons may fail to develop detectable antibody after Herpes infection.